| 1 |
29931583 | Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. | 2019 Apr |
1 |
| 2 |
31117849 | Current perspectives on the treatment of double hit lymphoma. | 2019 Jul |
1 |
| 3 |
31752970 | Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma. | 2019 Nov 21 |
1 |
| 4 |
29353886 | The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. | 2018 Apr |
1 |
| 5 |
28061782 | Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma. | 2017 Jan 7 |
1 |
| 6 |
28711572 | Emerging Strategies in Treating Double Hit Lymphomas. | 2017 Sep |
1 |
| 7 |
28766546 | [Diffuse large B-cell lymphoma with concomitant c-MYC and BCL6 gene rearrangements with primary skin involvement: A case report and a review of literature]. | 2017 |
1 |
| 8 |
26834954 | Current challenges and novel treatment strategies in double hit lymphomas. | 2016 Feb |
1 |
| 9 |
24679006 | TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations. | 2015 Jan |
1 |
| 10 |
26717387 | Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study. | 2015 Dec |
2 |
| 11 |
26824820 | [Diagnosis and treatment in patients with B-cell lymphoma unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma]. | 2015 |
2 |
| 12 |
24234731 | Current perspectives in genetics of "double-hit" lymphoma with possible clinical implications. | 2014 Jun |
1 |
| 13 |
21628860 | Double-hit lymphoma at second relapse of Burkitt-like lymphoma: a case report. | 2011 |
1 |
| 14 |
20118770 | B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. | 2010 Mar |
1 |